Drug company appoints David Schaffer to biologics advisory board — 3 insights

Written by Eric Oliver | September 13, 2019 | Print  |

Drug company Catalent named David Schaffer, PhD, to its biologics advisory board.

What you should know:

1. Dr. Schaffer has served in an advisory role since the company acquired Paragon Bioservices in May 2019.

2. Catalent formed the board in 2015 to support its efforts in the biologics space.

3. Dr. Schaffer is the current director of UC Berkeley's Berkeley Stem Cell Center. He earned his doctorate in chemical engineering from the Massachusetts Institute of Technology in Cambridge.

More articles on biologics:
Smith & Nephew, VirtaMed partner to provide arthroscopic simulation training
PE portfolio company Spine & Sports Physical Therapy acquires California physical therapy practice — 3 insights
Emory University surgeons publish spine surgery textbook

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months